Iksuda Therapeutics
PrivateLast Round
Strategic
Jun 15, 2025
Est. Valuation
$93.98M
Total Funding Raised
$68.75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Iksuda Therapeutics is a clinical-stage biotechnology company that specializes in the development of next-generation Antibody-Drug Conjugates (ADCs) for treating cancers with high unmet needs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iksuda Therapeutics Comparables
Compare Iksuda Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MediLink Therapeutics | 83% | |
| Sutro Biopharma Inc | 82% | |
| Seekyo | 81% |
Iksuda Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jun 15, 2025 | ||||
| Corporate Funding | Mar 21, 2025 | ||||
| Strategic | Nov 15, 2024 | ||||
| Series A | Jun 7, 2021 | ||||
| Grant | Jun 6, 2017 | ||||
Grant | Jul 27, 2015 |
Iksuda Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LigaChem Biosciences | Corporate Funding, Strategic |
| IP Group | Series A, Seed |
| North East Access to Finance | Seed |
| Premier Partners | Series A |
| Mirae Asset Securities | Series A |
| Centre for Process Innovation | Grant |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 40% MoM, reaching 4K.
- Jul 25, 2026
Monthly visitors grew 41% MoM, reaching 2.8K.
Iksuda Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Iksuda Therapeutics's valuation, stock price, and market status.
Is Iksuda Therapeutics a public or private company?
Iksuda Therapeutics is a private company.
What is the current stock price of Iksuda Therapeutics?
Iksuda Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Iksuda Therapeutics worth (valuation)?
Iksuda Therapeutics's valuation is estimated at $94.0M based on funding round data.
Can I buy Iksuda Therapeutics stock?
Iksuda Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Iksuda Therapeutics's last funding round?
Iksuda Therapeutics's most recent funding round was Strategic on November 15, 2024.
Who are the main investors in Iksuda Therapeutics?
Key investors in Iksuda Therapeutics include LigaChem Biosciences, Innovate UK, Mirae Asset Capital, Celltrion.
Will Iksuda Therapeutics IPO soon?
No public IPO plans have been announced for Iksuda Therapeutics.
How can I track Iksuda Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Iksuda Therapeutics's secondary market activity and sign up for updates.